FDA Eyes Alternatives To Generic-Drug Label Plan
The U.S. Food and Drug Administration on Tuesday reopened a comment period and scheduled a hearing to debate alternatives to its controversial plan to let generic-drug makers unilaterally update their warning...To view the full article, register now.
Already a subscriber? Click here to view full article